Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

All organisms possess molecular mechanisms that govern DNA repair and associated DNA
damage response (DDR) processes. Owing to their relevance to human disease, most …

DNA damage can alter nucleotide sequences and lead to expression of dysfunctional
proteins that impact normal cellular physiology. Sources of DNA damage can be …

Poly (ADP-ribose) polymerase (PARP) inhibitors are a therapeutic milestone exerting a
synthetic lethal effect in the treatment of cancer involving BRCA1/2 mutation. Theoretically …

High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of
ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified …

Inhibitors of poly-ADP-ribose polymerase 1 (PARPi) are highly effective in killing cells
deficient in homologous recombination (HR); thus, PARPi have been clinically utilized to …

TIGAR (TP53-induced glycolysis and apoptosis regulator) is the downstream target gene of
p53, contains a functional sequence similar to 6-phosphofructose kinase/fructose-2, 6 …

Molecular targeted therapy has revolutionized the landscape of cancer treatment due to
better therapeutic responses and less systemic toxicity. However, therapeutic resistance is a …

Ovarian cancer is one of the most lethal gynecologic malignancies reported throughout the
world. The initial, standard-of-care, adjuvant chemotherapy in epithelial ovarian cancer is …

Metabolic rewiring offers novel therapeutic opportunities in cancer. Until recently, there was
scant information regarding soft tissue sarcomas, due to their heterogeneous tissue origin …